Open AccessIs Fidaxomicin Worth the Cost? An Economic Analysis
Author(s) -
Sarah M. Bartsch,
Craig A. Umscheid,
Neil O. Fishman,
Bruce Y. Lee
Publication year - 2013
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/cit346
Subject(s) - medicine , fidaxomicin , intensive care medicine , vancomycin , biology , bacteria , genetics , staphylococcus aureus
In May 2011, the Food and Drug Administration approved fidaxomicin for the treatment of Clostridium difficile infection (CDI). It has been found to be noninferior to vancomycin; however, its cost-effectiveness for the treatment of CDI remains undetermined.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom